CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for OncoCyte Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

OncoCyte Corp
15 CUSHING
Phone: (949) 409-7600p:949 409-7600 Irvine, CA  92618  United States Ticker: OCXOCX
Business Summary
Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Company’s products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board AndrewArno 64 1/1/2023 6/1/2015
President, Chief Executive Officer, Director JoshuaRiggs 42 2/28/2023 12/2/2022
Chief Financial Officer, Principal Financial Officer Andrea S.James 6/17/2024 6/17/2024
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Chronix Biomedical 5941 Optical Court San Jose CA United States
Insight Genetics, Inc. 111 10th Ave South Nashville TN United States

Business Names
Business Name
Chronix Biomedical
Chronix Biomedical GmbH
Chronix Biomedical, Inc.
Insight Genetics, Inc.
OCX

General Information
Number of Employees: 43 (As of 12/31/2023)
Outstanding Shares: 16,835,247 (As of 10/15/2024)
Shareholders: 163
Stock Exchange: NASD
Federal Tax Id: 271041563
Fax Number: (510) 521-3389
Email Address: info@OncoCyte.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024